Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28337754 | 0.86 | DHFR (0.52) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL4335673 | 0.78 | DHFR (0.56) | DHFRALDH1A1 | |
| SCHEMBL30488023 | 0.77 | DHFR (0.56) | DHFRSMN1; SMN2MEN1ALDH1A1TSHR | |
| SCHEMBL1388631 | 0.77 | DHFR (0.56) | DHFRSMN1; SMN2MEN1ALDH1A1TSHR | |
| SCHEMBL2437579 | 0.76 | DHFR (0.67) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL1614076 | 0.76 | DHFR (0.55) | DHFRTSHRHTT | |
| SCHEMBL1613741 | 0.76 | DHFR (0.55) | DHFRHTT | |
| SCHEMBL27641705 | 0.76 | DHFR (0.57) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL642228 | 0.75 | HDAC4 (0.58) | LMNASMN1; SMN2ALDH1A1HSD17B10HTT | |
| SCHEMBL11643177 | 0.75 | DHFR (0.64) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101115761-A | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC (US) | 2008-01-30 | — | — | CN | claimed |
| CN-1625602-A | Method for selecting drug sensitivity decision factor and method for predetermining drug sensitivity using the selected factor | HOFFMANN LA ROCHE (CH) | 2005-06-08 | — | — | CN | claimed |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20120253039-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| CN-101115761-B | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC | 2012-07-18 | — | — | CN | disclosed |
| CN-102174024-A | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| CN-1625400-B | 2, 4-pyrimidinediamine compounds and uses thereof | RIGEL PHARMACEUTICALS INC | 2011-04-13 | — | — | CN | disclosed |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-7582648-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1981856-A2 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| CN-101115761-A | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| US-20070167439-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-7122542-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050234049-A1 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | MIDCAP FINANCIAL TRUST | 2005-10-20 | — | — | US | disclosed |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| CN-1625602-A | Method for selecting drug sensitivity decision factor and method for predetermining drug sensitivity using the selected factor | HOFFMANN LA ROCHE (CH) | 2005-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | DHFR 121/4885LMNA 2930/4885SMN1; SMN2 1436/4885 |
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | DHFR 321/4885LMNA 1834/4885SMN1; SMN2 2135/4885 |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TPMT, ADAR | DHFR 97/4885LMNA 2981/4885SMN1; SMN2 1284/4885 |
| US-20120253039-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | DHFR 121/4885LMNA 2930/4885SMN1; SMN2 1436/4885 |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | DHFR 121/4885LMNA 2930/4885SMN1; SMN2 1436/4885 |
| US-20070167439-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | DHFR 321/4885LMNA 1834/4885SMN1; SMN2 2135/4885 |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | DHFR 321/4885LMNA 1834/4885SMN1; SMN2 2135/4885 |
| US-20050234049-A1 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | SSB, HRH4, TLR7 | DHFR 676/4885LMNA 715/4885SMN1; SMN2 1702/4885 |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | SSB, TYMS, TPMT | DHFR 321/4885LMNA 1834/4885SMN1; SMN2 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.